Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
21 okt 2008 - 12:07
Statutaire naam
Crucell N.V.
Titel
Crucell Doubles Production of Quinvaxem® in 2008 and Prepares Move to New Korean Production Site to Facilitate Growth
Bericht
Leiden, The Netherlands, 21 October 2008 – Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that an agreement was reached to relocate Crucell’s Korean production facility, where its pentavalent children’s vaccine Quinvaxem® and a hepatitis B vaccine Hepavax-Gene® are produced, from the Shingal site in Yongin City, Korea to the Incheon Free Economic Zone.
All parties involved have agreed on the time line and conditions of this relocation, enabling a smooth transition to the new production facility. With engineering well underway, construction activities at the new site are due to start soon. The new facility will enable the further growth and efficient production of Quinvaxem® and Hepavax-Gene®. No further details were provided.
Datum laatste update: 01 september 2024